Frontline treatment approaches in TP53-aberrant mantle cell lymphoma

Click to increase image sizeClick to decrease image size

Acknowledgements

We would like to thank Angela Reagan for her administrative assistance throughout this study. Editorial assistance was provided by the Moffitt Cancer Center’s Office of Scientific Writing by Dr. Paul Fletcher & Daley Drucker. No compensation was given beyond their regular salaries.

Author contributions

NS: study design, data review, manuscript writing/revision; FCT, MD: data review, manuscript writing/revision; JW: statistical analysis; DB: statistical analysis; JSS: manuscript writing/revision; JC: manuscript writing/revision, LI: manuscript writing/revision, HS: manuscript writing/revision, MH: data collection, manuscript writing/revision; CB: manuscript writing/revision, LS: manuscript writing/revision, JPI: manuscript writing/revision, and BS: study design, study oversight and mentorship; data review, manuscript writing/revision.

Disclosure statement

NS: speaker honoraria, MJH Life Sciences; JSS: Speaker’s bureau: BMS. Advisory boards: SeaGen, TG therapeutics, MorphoSys; MH: Consultation and Honoraria for Adaptive Biotechnology, Stemline, Amgen, Seattle Genetics, Celgene/BMS, Boston Biomedical, Decibio, Bristol Myer Squibb, Wells Fargo, Pivot SG: Speaker’s bureau: TG therapeutics, Pharmacyclics. Advisory/consulting: Celgene, ADC therapeutics, Janssen, Epizyme, Beigene; HS: Consulting, advisory, or speaker’s compensation: Sanofi Pharm, Seagen, Inc., Bayer Healthcare AG, Epizyme, Inc., MorphoSys, Prime education; JC: research support from Kite, Novartis, Genentech, and AstraZeneca; LS: Consultations: Dren Bio, advisory board: Kyowa-Kirin; JPI: honoraria for consulting from Novartis and Bristol-Myers Squibb and is on the speakers’ bureau of Takeda; BS: received commercial research grants from Incyte and Jazz Pharma and is an advisory board member/unpaid consultant for Kite/Gilead, Celgene/Juno, Novartis, Adaptive, AstraZeneca, Pharmacyclics, and Spectrum/Acrotech; no potential conflicts of interest were disclosed by the other authors.

Additional information

Funding

This work has been supported in part by the Biostatistics & Bioinformatics Shared Resource at the H. Lee Moffitt Cancer Center & Research Institute, a comprehensive cancer center designated by the National Cancer Institute and funded in part by Moffitt’s Cancer Center Support Grant (P30-CA076292).